华海药业：多西环素胶囊获得美国FDA批准文号

Core Viewpoint - Huahai Pharmaceutical has received regulatory approvals for new drug indications and applications, indicating progress in its product pipeline and potential market expansion [1] Group 1: Regulatory Approvals - Huahai Pharmaceutical's subsidiary Huao Tai and Huabo Biotech received approval from the National Medical Products Administration for clinical trials of HB0017 injection for the new indication of suppurative hidradenitis [1] - The company has also received notification from the U.S. Food and Drug Administration (FDA) that its abbreviated new drug application for doxycycline capsules has been approved, which are primarily used for treating papulopustular rosacea [1]